CVS Health Corporation (NYSE:CVS) is one of the most undervalued blue chip stocks to buy now. Bernstein Raises PT on CVS Health (CVS) to $91, Reiterates ‘Market Perform’ Rating On January 6, 2026, Bernstein increased its price target on CVS Health Corporation (NYSE:CVS) from $87 to $91, while reiterating a ‘Market Perform’ rating. The investment firm expects a broader inflection in the government-managed care organization (MCO) sector beginning in 2026. The firm projects short-term earnings recovery, dri ...

Core Insights - Alger Spectra Fund's Class A shares outperformed the Russell 3000 Growth Index in Q2 2025, following a significant rebound in equities after a challenging Q1 [1] - The fund highlighted UnitedHealth Group Incorporated (NYSE:UNH) as a key stock, which saw a one-month return of 13.60% but experienced a 40.66% decline over the past 52 weeks [2] Company Performance - UnitedHealth Group reported revenues of nearly $112 billion in Q2 2025, reflecting a 13% increase compared to the same quarter last year [4] - The company integrates various healthcare services, leveraging its scale to manage rising healthcare costs, but faced challenges due to higher-than-expected utilization rates among Medicare Advantage members [3] Market Position - UnitedHealth Group is ranked 18th among the 30 Most Popular Stocks Among Hedge Funds, with 159 hedge fund portfolios holding its stock at the end of Q2 2025, up from 139 in the previous quarter [4] - Despite its strong market position, the company’s stock performance was negatively impacted by lower-than-expected fiscal first-quarter earnings and reduced full-year guidance due to unexpected cost pressures [3]